Leukemia Treatment Could Involve Drugs That Block DNA Repair Defects
the Cancer Therapy Advisor take:
According to a new study published in the journal Cell Reports at the National University of Singapore (NUS) in Singapore, Singapore, researchers have discovered a drug that may be useful for the treatment of leukemia and other cancers in which cancer cells have DNA repair defects.
The drug, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with standard chemotherapy could be more effective at treating leukemia than chemotherapy alone. In addition, the researchers found that the inhibition of Runt-related transcription factor (RUNX) genes causes DNA repair defects and promotes the development and growth of leukemia and other cancers.
RUNX genes are often inactivated in leukemia and other cancers. Specifically, RUNX1 is frequently mutated in leukemia and RUNX3 is linked to the development of the disease. According to Motomi Osato, MD, PhD, senior principal investigator from the Cancer Science Institute of Singapore at the NUS, PARP inhibitors have been around for a while, but this study demonstrates their effect on leukemia and other cancers.
The team is also conducting a preclinical study with PARP inhibitors to test drug efficacy. There are currently no PARP inhibitors approved by the U.S. Food and Drug Administration, but there are some undergoing clinical trials.
A drug originally designed for killing cancer cells could potentially be used to treat leukaemia.
DNA Damage Persistent DNA damage, visualized by gammaH2AX staining (red dots), in hematopoietic stem cells could lead to leukemia. Credit: National University of Singapore The new study suggests that treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, together with standard chemotherapy drugs, could be more effective in combating leukaemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol